WUXI, China, April 6, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA...
from PR Newswire: https://ift.tt/2PHkIbJ
No comments:
Post a Comment